Eli Lilly and Company
Organisation
Trials
Phase 4Not yet recruiting50 people24 Sept 2026clinicaltrials.gov
CollaboratorPhase 3Not yet recruiting70 people18 Sept 2026clinicaltrials.gov
Phase 3Not yet recruiting150 people14 Sept 2026clinicaltrials.gov
Phase 1Recruiting18 people4 Sept 2026clinicaltrials.gov
Phase 3Recruiting2,001 people31 Aug 2026clinicaltrials.gov
Phase 3Not yet recruiting192 people27 Aug 2026clinicaltrials.gov
CollaboratorPhase 4Not yet recruiting20 people10 Aug 2026clinicaltrials.gov
CollaboratorPhase 2Recruiting20 people29 Jul 2026clinicaltrials.gov
Phase 3Not yet recruiting170 people25 Jun 2026clinicaltrials.gov
Phase 3Recruiting130 people29 May 2026clinicaltrials.gov
Phase 3Recruiting550 people22 May 2026clinicaltrials.gov
Phase 2Recruiting350 people15 May 2026clinicaltrials.gov
Phase 3Recruiting140 people6 May 2026clinicaltrials.gov
Phase 4Active, not recruiting344 people27 Feb 2026clinicaltrials.gov
Phase 3Active, not recruiting600 people22 Jan 2026clinicaltrials.gov
Phase 1Recruiting123 people14 Jan 2026clinicaltrials.gov
Phase 1Completed20 people2 Jan 2026clinicaltrials.gov
Phase 1Active, not recruiting40 people23 Dec 2025clinicaltrials.gov
Phase 2Recruiting600 people17 Dec 2025clinicaltrials.gov
Phase 4Recruiting3,000 people25 Nov 2025clinicaltrials.gov
Funded papers
Papers
Orforglipron matches insulin glargine on cardiovascular safety
Lancet (London, England)1 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
The New England journal of medicine1 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet (London, England)30 Sept 2026